ARIUS successfully met its year one obligations and received all scheduled research payments from Takeda.
Additional Product Updates
Additionally, ARIUS continues to progress several other antibody candidates and has antibody programs targeting the MCSP antigen, AR005 antigen, and 37LRP in addition to several other undisclosed programs.
As part of its corporate governance review, ARIUS' Board of Directors has decided to nominate Mr. Carl Gordon as non-executive Chair of the Board of Directors. Dr. Young remains as President and Chief Executive Officer of the Company.
During the quarter, ARIUS' Executive Vice President and Chief Business Officer, Helen Findlay, left the Company to pursue other opportunities. In Ms. Findlay's role, she contributed to ARIUS' partnering and financing activities, helping to establish ARIUS on the path to becoming a clinical company.
All amounts are in Canadian dollars unless otherwise indicated.
For the nine-month period ended August 31, 2007, the Company recorded a
net loss of $8,104,701 ($0.18 per share) compared to a net loss of
$2,820,462 ($0.09 per share) for the same period in fiscal 2006. The
increase in net loss was the result of lower revenue, higher research and
development expenses and higher general and administrative costs offset
partially by lower interest expense and higher interest income. For the
three-month period ended August 31, 2007, the Company recorded a net loss
of $2,761,874 ($0.06 per share) compared to a net loss of $1,469,728 ($0.03
per share) for the three-month period ended August 31, 2006. This increase
in net loss for the three-month period is primarily the result of higher
research and development expenses, higher general
|SOURCE ARIUS Research Inc.|
Copyright©2007 PR Newswire.
All rights reserved